Trials / Completed
CompletedNCT03097068
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Vitreo-Retinal Associates, Michigan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Detailed description
Lucentis injections are the current standard of care for diabetic macular edema. The only deviation from the standard of care in the current protocol is an aqueous tap before the first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lucentis | 0.3mg Lucentis |
Timeline
- Start date
- 2017-04-19
- Primary completion
- 2017-12-06
- Completion
- 2018-02-02
- First posted
- 2017-03-31
- Last updated
- 2022-10-24
- Results posted
- 2022-10-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03097068. Inclusion in this directory is not an endorsement.